Return on assets of Coherus BioSciences, Inc.
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non?small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
|NIHD NII Holdings, Inc.||NASDAQ > Public Utilities > Telecommunications Equipment||$474.3M|
|NTRA Natera, Inc.||NASDAQ > Health Care > Medical Specialities||$474.97M|
|WTBA West Bancorporation||NASDAQ > Finance > Major Banks||$475.27M|
|HCCI Heritage-Crystal Clean, Inc.||NASDAQ > Basic Industries > Miscellaneous||$476.82M|
|MNKD MannKind Corporation||NASDAQ > Health Care > Major Pharmaceuticals||$477.87M|
|BPT BP Prudhoe Bay Royalty Trust||NYSE > Energy > Integrated oil Companies||$478.35M|
|CHRS Coherus BioSciences, Inc.||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||$478.51M|
|HDB HDFC Bank Limited||NYSE > Finance > Commercial Banks||$527.41B|
|MSFT Microsoft Corporation||NASDAQ > Technology > Computer Software: Prepackaged Software||$663.03B|
|GOOG Alphabet Inc.||NASDAQ > Technology > Computer Software: Programming, Data Processing||$663.31B|
|GOOGL Alphabet Inc.||NASDAQ > Technology > Computer Software: Programming, Data Processing||$663.8B|
|AMZN Amazon.com, Inc.||NASDAQ > Consumer Services > Catalog/Specialty Distribution||$714.48B|
|AAPL Apple Inc.||NASDAQ > Technology > Computer Manufacturing||$920.16B|